Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies

Abstract

Ultra-deep next-generation sequencing has emerged in recent years as an important diagnostic tool for the detection and follow-up of tumor burden in most of the known hematopoietic malignancies. Meticulous and high-throughput methods for the lowest possible quantified disease are needed to address the deficiencies of more classical techniques. Precision-based approaches will allow us to correctly stratify each patient based on the minimal residual disease (MRD) after a treatment cycle. In this review, we consider the most prominent ways to approach next-generation sequencing methodologies to follow-up MRD in hematological neoplasms.

Keywords

• minimal residual disease
• next-generation sequencing
• clonal evolution
• hematological neoplasms
• high-throughput sequencing